Insider Buying: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Purchases 122,221 Shares of Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Gordon Dunn purchased 122,221 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the completion of the purchase, the chief financial officer now directly owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. This trade represents a 423.55 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX stock opened at $0.55 on Monday. Quoin Pharmaceuticals, Ltd. has a fifty-two week low of $0.43 and a fifty-two week high of $6.18. The company has a 50 day moving average price of $0.68 and a 200 day moving average price of $0.63. The stock has a market capitalization of $2.78 million, a P/E ratio of -0.14 and a beta of 1.79.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.